Evidence map›Paper›PMID 38515568›Full record

ArticleFrontiers in oncology2024

Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review.

Valérian Rivet, Vincent Sibaud, Jérémie Dion, Thibaut Volosov, Mélanie Biteau, Andréa Pastissier, Karen Delavigne, Pierre Cougoul, Odile Rauzy, Thibault Comont

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valérian RivetInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Vincent SibaudDermatology Department - Medical Oncology, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Jérémie DionInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Thibaut VolosovThe Anatomical Pathology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Mélanie BiteauInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Andréa PastissierInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Karen DelavigneInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Pierre CougoulInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Odile RauzyInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Thibault ComontInternal Medicine and Immunopthology Department, The Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France.
Institut universitaire du cancer de Toulouse Oncopole · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) are used in several advanced malignancies and may cause various immune-related adverse events (irAEs). Among them, hematological irAEs are less described. Acquired amegakaryocytic thrombocytopenia (AAT) is a rare immune hematologic disorder characterized by severe thrombocytopenia and complete absence of megakaryocytes in bone marrow. Case presentation: Herein, we present the case of a patient in their 40s with metastatic melanoma who developed an AAT after 12 cycles of nivolumab (anti-PD1). His platelet count decreased by ≤5 × 10 Discussion: Four other cases are described on literature with the same features than non-ICI-related AAT. All cases occurred after anti-PD/PD-L1 treatment with a median onset of 5 weeks. The presentation of our case is quite different with delayed cytopenia. Both ciclosporin and TPO-RA seem to be efficient therapies. Conclusion: TPO-RA could be preferred in oncologic patients, but safety data are still missing to define clear guidelines for immune-related AAT management.

Indexed as

acquired megakaryocytic thrombocytopeniaeltrombopagimmune checkpoint inhibitors (ICI)immune-related adverse events (IRAE)nivolumabthrombopoietin receptor agonist (TPO-RA)

Identifiers

PMID38515568
PMCPMC10955628
OpenAlexW4392552995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.